aVCU Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
bDepartment of Internal Medicine, ASST Sette Laghi, Varese, Italy
cCardiothoracic Department, University Hospital "Santa Maria della Misericordia", Udine, Italy
dCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland clinic, Cleveland, OH, United States
eDivision of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Rochester, Minnesota, USA
fRobert M. Berne Cardiovascular Research Center and Division of Cardiology, Department of Internal Medicine, Heart and Vascular Center, University of Virginia, Charlottesville, VA, USA
Corresponding Author: Georgia K. Thomas, MD, PhD Assistant Professor of Medicine VCU Pauley Heart Center Virginia Commonwealth University 1200 East Broad Street Richmond, Virginia 23298 PO Box 980335 Email: [email protected]
The authors declare no conflicts of interest
Disclosures: Dr. Allan Klein is on the advisory board for Kiniksa Pharmaceuticals, Cardiol Therapeutics, and Pfizer. Dr. Antonio Abbate has received research grant funding and has served as a paid scientific advisor to GSK, Kiniksa Pharmaceuticals, Merck, Novartis, Olatec, Serpin Pharma, R-Pharm, and Swedish Orpha Biovitrum. The remaining authors have nothing to disclose.
Funding information: None.
